2019
Prevalence and role of HER2 mutations in cancer
Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacology & Therapeutics 2019, 199: 188-196. PMID: 30951733, PMCID: PMC6571037, DOI: 10.1016/j.pharmthera.2019.03.010.Peer-Reviewed Original ResearchConceptsHER2 mutationsCell-free DNARecent clinical trialsNext-generation sequencingActivity of HER2Variety of tumorsPreclinical dataClinical trialsDifferent human cancersTumor biopsiesOncogenic driversClinical settingCancer typesHER2Human cancersTherapyCancerPrevalenceVariable sensitivityGeneration sequencingMutationsBiological characterizationBiopsyClinicTumors
2012
EGFR/HER-targeted therapeutics in ovarian cancer
Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry 2012, 4: 447-469. PMID: 22416774, PMCID: PMC4620931, DOI: 10.4155/fmc.12.11.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerHuman epidermal growth factor receptor (HER) familyEpidermal growth factor receptor familyGrowth factor receptor familyTreatment modalitiesFactor receptor familyClinical developmentDiverse malignanciesEGFR/Clinical settingUS FDACancerNew drugsReceptor familyPatientsMalignancyTherapeuticsTreatmentTyrosine kinaseSurvivalSame periodCarcinomaMajor roleEtiology